NanoVibronix Sees 33% Share Price Surge Ahead of Meeting

Introduction

NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company founded in September 2003 and headquartered in Elmsford, New York, with research and development operations in Nesher, Israel. The company develops and markets non-invasive therapeutic ultrasound products based on its proprietary low-intensity surface acoustic wave technology. Its patch-based and catheter-based solutions—including PainShield®, WoundShield™, UroShield™, and NG-Shield™—are either cleared by the U.S. Food and Drug Administration or bear CE Mark certification for use in pain management and infection reduction.

Corporate Structure

NanoVibronix operates with a workforce of 11 to 50 employees. Key members of the leadership team include:

• Brian Murphy, Chief Executive Officer, with over 25 years in medical device sales and management
• Christopher Fashek, Chairman of the Board, a healthcare executive experienced in global medical-device businesses
• Harold Jacob, M.D., Chief Medical Officer and co-founder, with extensive device development and clinical experience
• Steve Brown, Chief Financial Officer, overseeing financial strategy
• Lindsey Harrison, Vice President of Sales, directing commercial efforts

The board also features Martin Goldstein, M.D., and other directors whose backgrounds include urology, biomedical innovation, and corporate governance.

Ultrasound Therapy by Rosa Rafael

Recent Developments and News

On June 9, 2025, NanoVibronix filed a preliminary proxy statement (Form PRE 14A) ahead of its Special Meeting of Stockholders. That meeting’s record date was set for May 16, 2025, with an initial scheduling for July 2, 2025. A subsequent filing on June 20, 2025 (Form DEF 14A), confirmed the Special Meeting date as July 11, 2025, and outlined voting procedures. On June 25, 2025, the company submitted an amended proxy statement (Form DEFA 14A) correcting the counts of preferred shares to 320,348 Series G and 57,720 Series X, with no Series C-F shares outstanding. In trading on June 27, 2025, the share price closed at $1.16, an intraday increase of 33.47%, on a volume of 3,433,008 shares.

Financial and Strategic Aspects

As of June 26, 2025, NanoVibronix reported an enterprise value of approximately $5.4 million and a market capitalization near $2.1 million. Its trailing twelve-month revenue totaled $2.66 million, while net losses amounted to $5.61 million, resulting in a diluted EPS of –14.06. The profit margin was recorded at –210.82%, return on assets at –12.08%, and return on equity at –28.65%. The balance sheet indicated cash reserves of $601,000 and a debt-to-equity ratio of 10.98%. The company continues to seek regulatory clearances for its ultrasound platforms while pursuing commercial partnerships aimed at addressing pain relief and catheter-associated urinary tract infections.

Market Position and Industry Context

NanoVibronix operates within the medical equipment manufacturing sector, focusing on non-invasive therapeutic ultrasound as an alternative to pharmacological treatments. Its FDA-cleared and CE-marked products are differentiated by their self-adhesive, wearable patches and catheter-integrated devices. Key markets include the United States, Europe, Australia, India, and Israel. The company’s technology addresses the increasing demand for alternatives to opioids in pain management and infection control.

tl;dr

On June 27, 2025, NanoVibronix shares closed at $1.16, up 33.47% on a volume of 3.43 million. The company filed amended proxy materials on June 25, 2025, correcting preferred share counts and confirming a July 11, 2025, Special Meeting of Stockholders. Fiscal year-to-date revenue stands at $2.66 million against a net loss of $5.61 million, with cash of $601,000 and modest leverage. Upcoming regulatory milestones, shareholder votes, and commercial adoption of its ultrasound platforms will influence the company's outlook.